Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Although this difference did not reach statistical significance for iDFS (HR, 0.78 [95% CI, 0.58 to 1.06]; P = .12), the improvement magnitude would be considered as clinically meaningful, which was comparable with ours. 17 Different ethnic background, back bone regimen, or patient selection may have influenced the results.

also in 111,027 other papers